University of Sussex
Browse
- No file added yet -

No man’s land: information needs and resources of men with metastatic castrate resistant prostate cancer

Download (228.95 kB)
journal contribution
posted on 2023-06-09, 02:23 authored by Valerie JenkinsValerie Jenkins, Lesley FallowfieldLesley Fallowfield
The majority of men treated for prostate cancer will eventually develop castrate resistant disease (CRPC) with metastases (mCRPC). There are several options for further treatment: chemotherapy, third-line hormone therapy, radium, immunotherapy and palliation. Current ASCO guidelines for survivors of prostate cancer recommend that an individual’s information needs at all stages of disease are assessed, and that patients are provided with or referred to the appropriate sources for information and support. Earlier reviews have highlighted the dearth of such services and we wished to see if the situation had improved more recently. Unfortunately we conclude that there is still a lack of good quality congruent information easily accessible specifically for men with mCRPC and insufficient data regarding the risks, harms and benefits of different management plans. More research providing a clear evidence base about treatment consequences using patient reported outcome measures is required.

Funding

EXPECT; G1580; pH Associates and Sanofi

History

Publication status

  • Published

File Version

  • Accepted version

Journal

Supportive Care in Cancer

ISSN

0941-4355

Publisher

Springer Verlag

Issue

11

Volume

24

Page range

4471-4473

Department affiliated with

  • Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2016-08-04

First Open Access (FOA) Date

2017-07-29

First Compliant Deposit (FCD) Date

2016-08-04

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC